مباشر
Endpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugClinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease RiskEndpoints NewsEli Lilly's claims data deadline may kick off new 340B fightClinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed ResultsAgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.comEndpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapyClinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected FutureFierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EYFierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx marketBioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studiesEndpoints NewsA different approach to lowering healthcare costsCellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity
Insilico Medicine ٢٠ أبريل ٢٠٢٦

Insilico Medicine Advances AI-Driven Target Discovery with Validated TargetPro–TargetBench Framework - Insilico Medicine

Insilico Medicine Advances AI-Driven Target Discovery with Validated TargetPro–TargetBench Framework - Insilico Medicine

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.